18 years. 2+ billion doses and counting.
Our pipeline of medicines aims to overcome barriers that patients face with existing treatment options and provide new paradigms for treating critical and complex conditions.1
2B+ doses consumed. 200+ patents provide strong intellectual property.
Aquestive is the worldwide leader in delivering trusted, quality medications on oral film. Every medicine is different, so Aquestive follows a drug-by-drug approach for harnessing PharmFilm® technology to achieve target product profiles and clinical improvement goals.
Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology. We’ve used our expertise to create a robust, proprietary, and complex molecule portfolio.
Learn about the medicines we’re reinventing to improve treatment options for patients.
Anaphylaxis is a serious systemic hypersensitivity reaction. Aquestive is developing AQST-109, a sublingual film that, if approved by the FDA, will allow patients to simply place a dissolvable strip, approximately the size and weight of a postage stamp, under the tongue to provide rapid delivery of epinephrine when it is needed.
PharmFilm® is a versatile, high-performance drug delivery technology that can be uniquely tailored to achieve a desired product profile with optimized absorption, bioavailability, and onset of action.
See how Aquestive is changing drug delivery to deliver meaningful clinical and therapeutic advances.
Aquestive is a pharmaceutical company aiming to solve patients’ problems by advancing current standards of care through simplifying complex delivery methods. Aquestive is developing orally administered products to provide novel alternatives to invasive and inconvenient standard of care therapies. Our focus is to improve medications and outcomes for patients with central nervous system (CNS) conditions and severe allergies, including anaphylaxis.
We work hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a simplified development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.
Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance Reaffirms commitment to pursue early market access for Libervant™ (diazepam) Buccal Film Obtains
WARREN, N.J. , April 26, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team
WARREN, N.J. , April 20, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today
1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.
2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.